Wave Life Sciences Ltd. (WVE)
NASDAQ: WVE · Real-Time Price · USD
9.97
+0.03 (0.30%)
At close: Aug 26, 2025, 4:00 PM
9.97
0.00 (0.00%)
After-hours: Aug 26, 2025, 4:00 PM EDT
Wave Life Sciences Stock Forecast
Stock Price Forecast
The 16 analysts that cover Wave Life Sciences stock have a consensus rating of "Strong Buy" and an average price target of $20, which forecasts a 100.60% increase in the stock price over the next year. The lowest target is $10 and the highest is $36.
Price Target: $20 (+100.60%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Wave Life Sciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
---|---|---|---|---|---|---|
Strong Buy | 6 | 5 | 5 | 5 | 6 | 7 |
Buy | 4 | 5 | 5 | 7 | 8 | 8 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 11 | 11 | 11 | 13 | 15 | 16 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $19 | Strong Buy | Initiates | $19 | +90.57% | Aug 4, 2025 |
Wells Fargo | Wells Fargo | Buy Maintains $24 → $21 | Buy | Maintains | $24 → $21 | +110.63% | Jul 31, 2025 |
Oppenheimer | Oppenheimer | Buy Initiates $24 | Buy | Initiates | $24 | +140.72% | Jul 28, 2025 |
Citigroup | Citigroup | Strong Buy Initiates $16 | Strong Buy | Initiates | $16 | +60.48% | Jul 16, 2025 |
Wedbush | Wedbush | Buy Reiterates $18 | Buy | Reiterates | $18 | +80.54% | Jun 23, 2025 |
Financial Forecast
Revenue This Year
49.42M
from 108.30M
Decreased by -54.37%
Revenue Next Year
54.37M
from 49.42M
Increased by 10.02%
EPS This Year
-1.15
from -0.70
EPS Next Year
-1.20
from -1.15
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 89.3M | 126.0M | |||
Avg | 49.4M | 54.4M | |||
Low | 17.5M | n/a |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -17.6% | 155.0% | |||
Avg | -54.4% | 10.0% | |||
Low | -83.8% | - |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -0.97 | -0.84 | |||
Avg | -1.15 | -1.20 | |||
Low | -1.39 | -1.73 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | |||
Avg | - | - | |||
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.